Cardio Diagnostics与15个新的美国供应商组织建立合作伙伴关系，扩大其AI驱动的血液测试，Epi+Gen CHD和PrecisionCHD的采用，旨在改善各种临床环境中冠心病的预防，检测和管理

Growing Adoption of AI-Driven Precision Cardiovascular Medicine Tests Spans Concierge, Functional Medicine, and Primary Care Practices

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven Precision Cardiovascular Medicine company, today announced the Company has partnered with 15 new provider organizations across the United States. This expansion demonstrates the continued adoption of the Company's innovative blood tests, Epi+Gen CHD™ and PrecisionCHD™, which are transforming the prevention, detection, and management of coronary heart disease across diverse clinical settings.